| Patricia Mozzillo, | |
|
250 Pleasant St., Concord, NH 03301-7559 | |
| (603) 789-9103 | |
| (603) 227-7832 |
| Full Name | Patricia Mozzillo |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 10 Years |
| Location | 250 Pleasant St., Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609292028 | NPI | - | NPPES |
| 3097170 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 069608-23 (New Hampshire) | Primary |
| 163WC0200X | Registered Nurse - Critical Care Medicine | RN135701 (Arizona) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Concord Hospital | Concord, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Associates Professional Association | 3375532435 | 55 |
| Anesthesia Care Group Pc | 5395646178 | 62 |
| Concord Hospital Inc | 6103721790 | 462 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Entity Name | Anesthesia Care Group Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629074224 PECOS PAC ID: 5395646178 Enrollment ID: O20040115000446 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Entity Name | Concord Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194778571 PECOS PAC ID: 6103721790 Enrollment ID: O20040405000916 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Entity Name | Anesthesia Associates Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881791150 PECOS PAC ID: 3375532435 Enrollment ID: O20040512000620 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Entity Name | Amoskeag Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104883511 PECOS PAC ID: 1759375983 Enrollment ID: O20040513001385 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Entity Name | Catholic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1003692112 PECOS PAC ID: 6103897129 Enrollment ID: O20231122002805 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia Mozzillo, 250 Pleasant St, Concord, NH 03301-7559 Ph: (603) 789-9103 | Patricia Mozzillo, 250 Pleasant St., Concord, NH 03301-7559 Ph: (603) 789-9103 |
News Archive
Kessler Foundation received $65,500 as part of a two-year $140,000 grant from the ARSEP Foundation of France to the University of Bordeaux, to launch a collaborative study of emotional processing deficits in people with multiple sclerosis (MS). Helen Genova, Ph.D., and Jean Lengenfelder, Ph.D., of Kessler Foundation and Bruno Brochet, M.D., Ph.D., of the University of Bordeaux are the principal investigators.
Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.
ArunA Biomedical, Inc., has announced that it will make its CELL-EZ brand hMC human mesenchymal progenitor cells commercially available to the research community in mid 2009.
The research team tracked the health and survival of almost 116,000 women who had been diagnosed with primary invasive breast cancer in England and Wales between 1986 and 1990, using information supplied to the National Cancer Registry. Their progress was monitored until 1995.
› Verified 9 days ago
Andrew Hershey, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Louis Dumont, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Pillsbury St, Suite 202, Concord, NH 03301 Phone: 603-224-4776 Fax: 603-228-2113 | |
Christine A Burgess, C.R.N.A. Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Pillsbury St, Suite 202, Concord, NH 03301 Phone: 603-224-4776 Fax: 603-228-2113 | |
James V. Tyer, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Pillsbury St, Suite 202, Concord, NH 03301 Phone: 603-224-4776 Fax: 603-228-2113 | |
Mrs. Loranda Rene Palacios, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Bradley Stephen Donesky, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-789-9103 Fax: 603-227-7832 | |
Mrs. Katherine Grace Jones, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Pillsbury St, Suite 202, Concord, NH 03301 Phone: 603-224-4776 Fax: 603-228-2113 |